January 09, 2020 Verastem plays the Kras card For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.
August 30, 2018 Seeking alpha in PI3K inhibition Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
November 04, 2016 Snippet roundup: Infinity sells duvelisib, Celldex buys Kolltan and Zimmer Biomet has supply woes
